AlphAIalphai — Financial news for AI agents
fool.comAUG 193 min read$ANNX

Annexon (ANNX) Q2 2026 Earnings Call Transcript

Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. ARCHER II trial for geographic atrophy enrolled 659 patients, exceeding targets. Tanruprubart for Guillain-Barré syndrome (GBS) is on track for BLA submission in Q4 2026, with positive FORWARD study data. Operations are funded into 2028.

Original reporting
fool.com
Published Aug 19, 2026, 2:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 3:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Annexon (ANNX) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$ANNXNeutralMed
01

Why it matters

The disclosed cash balance and new credit facility extend runway to 2028, while trial enrollment exceeds targets, supporting long‑term valuation.

02

Market read

First public disclosure of Annexon's Q2 results and trial milestones provides actionable data for biotech traders.

03

What to watch

Potential regulatory timelines and competitive landscape in GA and GBS therapies.

Relevance 8/10Novelty 8/10Timing: post‑earnings Q2 2026 release

Background

Annexon provided its Q2 2026 earnings call transcript, detailing financial results and clinical program updates.

Company-level read

Ticker impact

$ANNXNeutralMedium confidence
Context

Q2 2026 earnings disclosed net loss of $55.3M, $209.2M cash, $200M credit facility, and Phase III ARCHER II trial updates.

Expected impact

Potential short-term volatility with upside if trial data continues to exceed expectations.

Evidence & confidence

New financials and trial milestones provide fresh data; market reaction will depend on guidance and data readouts.

Market effects

Sector

Biotech sector may see increased interest in complement‑inhibition therapies.

Regional

U.S. biotech investors likely to adjust exposure to early‑stage clinical companies.

Global

Positive trial data could influence global ophthalmology and neurology pipelines.

Counterpoint

What could challenge this read

Despite cash runway, rising R&D spend and widening loss could signal overextension.

Key entities

  • Executive
    Douglas Love

    President and CEO of Annexon.

  • Clinical Trial
    ARCHER II

    Phase III geographic atrophy study.

Read at source← All news

Related articles

AUG 22
$ANNXMed

Annexon (ANNX) Q2 2026 Earnings Call Transcript

Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. Key updates include ARCHER II trial progress in geographic atrophy and plans for a BLA submission for tanruprubart in Q4 2026. Management projects funding into 2028.

aol.com3 min
AUG 12
$ANNXMed

Annexon Q2 Earnings Call Highlights

Annexon (NASDAQ:ANNX) reported Q2 call highlights for its complement-targeted therapy tanruprubart in Guillain-Barre syndrome, saying patients showed rapid functional gains and ventilator weaning within days, with adverse events linked to GBS complications. The company also added a 24-month endpoint to ARCHER II for vonaprument, with 15-month review expected in Q4 2026 and results in 2027.

yahoo.com5 min
AUG 12
$ANNXMed

Annexon Advances C1q-Targeted Therapies; Tanruprubart BLA Filing And ARCHER II Data On The Horizon

Annexon Biosciences (ANNX) reported Q2 2026 results and clinical updates. It said Phase 3 FORWARD tanruprubart in Guillain-Barre has treated the first 10 U.S. and European patients and expects a Q4 2026 BLA filing. For vonaprument in geographic atrophy, ARCHER II remains on track with Month 15 data in Q4 2026 and final completion in Q3 2027. Q2 R&D was $46.6M, net loss $55.3M. Cash was $209.2M. A $200M credit facility was arranged with $50M drawn.

rttnews.com6 min
AUG 12
$SMCIHighAI 8/10

Super Micro jumps premarket on outlook boost, H&R Block surges

U.S. stock futures edged higher ahead of CPI, with investors watching for signals on the Fed’s rate path. In premarket movers, Super Micro Computer rose over 9% on full-year guidance above expectations. H&R Block gained 13.9% after Q4 adjusted EPS of $2.38 vs $2.31 consensus, revenue $3.95B, and FY27 EPS outlook $6.04-$6.24. Other movers included Owlet, Valens Semiconductor, and Riskified.

investing.com4 min
AUG 12
$ANNXMedAI 8/10

Annexon Biosciences: Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Annexon, Inc. (Nasdaq: ANNX) reported Q2 2026 results and clinical updates. It said tanruprubart GBS data support a Q4 2026 BLA submission, and vonaprument GA Phase 3 ARCHER II is on track with a Month 15 endpoint in Q4 2026 and Month 24 in Q3 2027. Cash was $209.2M at June 30, 2026; net loss was $55.3M. It also secured a $200M credit facility.

finanznachrichten.de7 min
AUG 12
$ANNXMed

Annexon Biosciences: Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label

Annexon, Inc. (Nasdaq: ANNX) said it added a Month 24 dual primary endpoint to its Phase 3 ARCHER II trial of vonaprument for geographic atrophy in dry AMD, alongside the existing Month 15 endpoint. It also launched an open-label extension for long-term safety and benefit. Month 15 DMC assessment is expected in Q4 2026, with Month 24 results in Q3 2027.

finanznachrichten.de3 min